<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937023</url>
  </required_header>
  <id_info>
    <org_study_id>SVSIDS/PERIO/1/2020</org_study_id>
    <nct_id>NCT04937023</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid (Udca) as a Local Drug Delivery Agent in the Treatment of Intra-bony Defects</brief_title>
  <official_title>Assessing the Clinical Efficacy of Ursodeoxycholic Acid (Udca) as a Local Drug Delivery Agent in the Treatment of Intra-bony Defects: A Clinico-radiographic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SVS Institute of Dental Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SVS Institute of Dental Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of ursodeoxycholic acid as local drug&#xD;
      delivery agent in intra- bony defect to achieve bone regeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental: Main treatment group the prepared UDCA gel will be injected using a syringe&#xD;
      with blunt cannula into the defect site.&#xD;
&#xD;
      Comparator: In patients allocated to control group, placebo gel will be injected in to the&#xD;
      defect site using a syringe with blunt cannula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of bone regeneration</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Radiovisiography (RVG) will be used to assess bone regeneration achieved post-operatively after 3 months and 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation if clinical attachment level</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Assessment of clinical attachment level (CAL) using UNC-15 probe at baseline and post-operatively at 3 and 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of probing pocket depth</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Assessment of probing pocket (PPD) depth using UNC- 15 probe at baseline and postoperatively at 3 and 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of gingiva</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Gingival index (GI) - according to Loe H and Silness P, 1963</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of gingival bleeding</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Gingival bleeding index - Ainamo and Bay, 1975</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Bone Regeneration</condition>
  <arm_group>
    <arm_group_label>UDCA gel will be injected using a syringe with blunt cannula into the defect site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the test group, the prepared UDCA gel will be injected using a syringe with blunt cannula into the two or three wall intra-bony defects with probing pocket depth â‰¥3mm after performing SRP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo gel will be injected in to the defect site using a syringe with blunt cannula.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In patients allocated to control group, placebo gel will be injected in to the defect site using a syringe with blunt cannula after scaling and root planing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid gel</intervention_name>
    <description>Following scaling and root planing in intrabony defects UDCA gel will be injected</description>
    <arm_group_label>UDCA gel will be injected using a syringe with blunt cannula into the defect site</arm_group_label>
    <arm_group_label>placebo gel will be injected in to the defect site using a syringe with blunt cannula.</arm_group_label>
    <other_name>experimental group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systemically healthy male and female patients of age&gt;18 years with intrabony defects -&#xD;
             two wall or three wall defects and probing pocket depths (PPD) of &gt;3mm will be&#xD;
             included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically compromised patients, pregnant women, heavy smokers, and patients who&#xD;
             underwent radiotherapy or chemotherapy will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>R V Chandra, MDS;DNB;PhD</last_name>
    <phone>9908183071</phone>
    <email>viswachandra@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SVS Institute of Dental Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>509002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R V Chandra, MDS;DNB;PhD</last_name>
      <phone>9908183071</phone>
      <email>viswachandra@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SVS Institute of Dental Sciences</investigator_affiliation>
    <investigator_full_name>Dr R Viswa Chandra</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

